275 related articles for article (PubMed ID: 10098743)
21. Presence of MLH1 protein aggravates the potential of the HSP90 inhibitor radicicol to sensitize tumor cells to cisplatin.
Fedier A; Stuedli A; Fink D
Int J Oncol; 2005 Dec; 27(6):1697-705. PubMed ID: 16273226
[TBL] [Abstract][Full Text] [Related]
22. MLH1-deficient tumor cells are resistant to lipoplatin, but retain sensitivity to lipoxal.
Fedier A; Poyet C; Perucchini D; Boulikas T; Fink D
Anticancer Drugs; 2006 Mar; 17(3):315-23. PubMed ID: 16520660
[TBL] [Abstract][Full Text] [Related]
23. Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells.
Papouli E; Cejka P; Jiricny J
Cancer Res; 2004 May; 64(10):3391-4. PubMed ID: 15150090
[TBL] [Abstract][Full Text] [Related]
24. Determination of cell fate by c-Abl activation in the response to DNA damage.
Kharbanda S; Yuan ZM; Weichselbaum R; Kufe D
Oncogene; 1998 Dec; 17(25):3309-18. PubMed ID: 9916993
[TBL] [Abstract][Full Text] [Related]
25. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage.
Gong JG; Costanzo A; Yang HQ; Melino G; Kaelin WG; Levrero M; Wang JY
Nature; 1999 Jun; 399(6738):806-9. PubMed ID: 10391249
[TBL] [Abstract][Full Text] [Related]
26. Monofunctional platinum-DNA adducts are strong inhibitors of transcription and substrates for nucleotide excision repair in live mammalian cells.
Zhu G; Myint M; Ang WH; Song L; Lippard SJ
Cancer Res; 2012 Feb; 72(3):790-800. PubMed ID: 22180496
[TBL] [Abstract][Full Text] [Related]
27. Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage.
Vikhanskaya F; Colella G; Valenti M; Parodi S; D'Incalci M; Broggini M
Clin Cancer Res; 1999 Apr; 5(4):937-41. PubMed ID: 10213232
[TBL] [Abstract][Full Text] [Related]
28. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells.
Rietbroek RC; van de Vaart PJ; Haveman J; Blommaert FA; Geerdink A; Bakker PJ; Veenhof CH
J Cancer Res Clin Oncol; 1997; 123(1):6-12. PubMed ID: 8996534
[TBL] [Abstract][Full Text] [Related]
29. Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin.
Fink D; Nebel S; Norris PS; Baergen RN; Wilczynski SP; Costa MJ; Haas M; Cannistra SA; Howell SB
Int J Cancer; 1998 Aug; 77(5):741-6. PubMed ID: 9688308
[TBL] [Abstract][Full Text] [Related]
30. MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells.
Park JM; Huang S; Tougeron D; Sinicrope FA
PLoS One; 2013; 8(5):e65369. PubMed ID: 23724141
[TBL] [Abstract][Full Text] [Related]
31. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.
Chaney SG; Campbell SL; Bassett E; Wu Y
Crit Rev Oncol Hematol; 2005 Jan; 53(1):3-11. PubMed ID: 15607931
[TBL] [Abstract][Full Text] [Related]
32. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin.
Lin X; Ramamurthi K; Mishima M; Kondo A; Christen RD; Howell SB
Cancer Res; 2001 Feb; 61(4):1508-16. PubMed ID: 11245458
[TBL] [Abstract][Full Text] [Related]
33. GADD45α modulates curcumin sensitivity through c-Abl- and JNK-dependent signaling pathways in a mismatch repair-dependent manner.
Naick H; Jin S; Baskaran R
Mol Cell Biochem; 2016 Mar; 414(1-2):13-22. PubMed ID: 26833194
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair.
Manic S; Gatti L; Carenini N; Fumagalli G; Zunino F; Perego P
Curr Cancer Drug Targets; 2003 Feb; 3(1):21-9. PubMed ID: 12570658
[TBL] [Abstract][Full Text] [Related]
35. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
Perego P; Gatti L; Righetti SC; Beretta GL; Carenini N; Corna E; Dal Bo L; Tinelli S; Colangelo D; Leone R; Apostoli P; Lombardi L; Beggiolin G; Piazzoni L; Zunino F
Int J Cancer; 2003 Jul; 105(5):617-24. PubMed ID: 12740909
[TBL] [Abstract][Full Text] [Related]
36. Human cells deficient in transcription-coupled repair show prolonged activation of the Jun N-terminal kinase and increased sensitivity following cisplatin treatment.
Bulmer JT; Zacal NJ; Rainbow AJ
Cancer Chemother Pharmacol; 2005 Aug; 56(2):189-98. PubMed ID: 15841377
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo modulations of benzo[c]phenanthrene-DNA adducts by DNA mismatch repair system.
Wu J; Zhu BB; Yu J; Zhu H; Qiu L; Kindy MS; Gu L; Seidel A; Li GM
Nucleic Acids Res; 2003 Nov; 31(22):6428-34. PubMed ID: 14602900
[TBL] [Abstract][Full Text] [Related]
38. The mismatch repair system is required for S-phase checkpoint activation.
Brown KD; Rathi A; Kamath R; Beardsley DI; Zhan Q; Mannino JL; Baskaran R
Nat Genet; 2003 Jan; 33(1):80-4. PubMed ID: 12447371
[TBL] [Abstract][Full Text] [Related]
39. Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation.
Domingo E; Espín E; Armengol M; Oliveira C; Pinto M; Duval A; Brennetot C; Seruca R; Hamelin R; Yamamoto H; Schwartz S
Genes Chromosomes Cancer; 2004 Feb; 39(2):138-42. PubMed ID: 14695993
[TBL] [Abstract][Full Text] [Related]
40. Oxaliplatin: mechanism of action and antineoplastic activity.
Raymond E; Faivre S; Woynarowski JM; Chaney SG
Semin Oncol; 1998 Apr; 25(2 Suppl 5):4-12. PubMed ID: 9609103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
